Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report

Journal Article · Thu Jul 01 00:00:00 EDT 1982 · Cancer Treat. Rep.; (United States)

OSTI ID:6941797

Murphy, S; Rosenthal, D S; Weinfeld, A; Briere, J; Faguet, G B; Knospe, W H; Landaw, S A; Laszlo, J; Pisciotta, A V; Tartaglia, A P; Goldberg, J D; Berk, P D; Donovan, P B; Wasserman, L R

Thirty-one patients with essential thrombocythemia were randomized to receive either melphalan or radioactive phosphorus as myelosuppressive therapy. Twenty-seven patients were evaluable for response. Of 13 patients treated with melphalan, 11 had a complete response (platelet count less than 450,000/mm3) at 3 and 6 months. This response rate was significantly better than the response to radioactive phosphorus. The response rates were similar at 12 months. No significant toxicity was observed with either regimen.

• Research Organization: Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA
• OSTI ID: 6941797
• Journal Information: Cancer Treat. Rep.; (United States), Vol. 66:7
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
62 RADIOLOGY AND NUCLEAR MEDICINE
BONE MARROW
BIOLOGICAL RADIATION EFFECTS
POLYCYTHEMIA
RADIOTHERAPY
BLOOD PLATELETS
INTERNAL IRRADIATION
PATIENTS
PHOSPHORUS ISOTOPES
SIDE EFFECTS
ANIMAL TISSUES
BIOLOGICAL EFFECTS
BIOLOGICAL MATERIALS
BLOOD
BLOOD CELLS
BODY
BODY FLUIDS
DISEASES
HEMATOPOIETIC SYSTEM
HEMIC DISEASES
IRRADIATION
ISOTOPES
MATERIALS
MEDICINE
NUCLEAR MEDICINE
ORGANS
RADIATION EFFECTS
RADIOLOGY
THERAPY
TISSUES
560151* - Radiation Effects on Animals- Man
550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)